<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611347</url>
  </required_header>
  <id_info>
    <org_study_id>HSR200147</org_study_id>
    <nct_id>NCT04611347</nct_id>
  </id_info>
  <brief_title>Topical CBD in Joint Arthritis</brief_title>
  <official_title>A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: CBD is commonly being used as an over-the-counter treatment for arthritis-related&#xD;
      pain, however no clinical trial has been performed to establish efficacy.&#xD;
&#xD;
      Hypothesis: CBD is more effective than placebo for relieving pain and improving&#xD;
      patient-reported outcomes for thumb basal joint arthritis.&#xD;
&#xD;
      Study Design: The study design with be a double-blind, randomized controlled trial with&#xD;
      crossover. Treatment will be blinded to the subjects and investigators. Patients will be&#xD;
      randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for&#xD;
      2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour.&#xD;
      Subjects will be advised to observe for physiologic changes, skin changes, or other adverse&#xD;
      effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Population: 40 subjects with presenting with thumb basal joint arthritis over the age&#xD;
      of 18 will be recruited from the UVA Hand Center.&#xD;
&#xD;
      Description of Sites/Facilities Enrolling Participants: This will be a single-site study&#xD;
      conducted at the UVA Hand Center at the University of Virginia.&#xD;
&#xD;
      Description of Study Intervention: The study design will be a double-blind randomized control&#xD;
      trial with crossover. Treatment will be blinded to the subjects and investigators. Patients&#xD;
      will be randomly assigned 2 weeks of the case (CBD) or control cream and then crossover to&#xD;
      the other cream for 2 more weeks. Patients will apply the topical cream at their thumb basal&#xD;
      joint one time daily for 1 hour. The subjects will be advised to observe for physiologic&#xD;
      changes, skin changes, or other adverse effects. If mild to serious adverse events are&#xD;
      noticed, the creams will be removed immediately and appropriate care and observation will be&#xD;
      taken. Each condition will last for 2 weeks and then subjects will be contacted by the study&#xD;
      coordinator to facilitate crossover into the other condition. To capture any delayed-onset&#xD;
      adverse events, including those related to skin changes that might develop after the drug is&#xD;
      discontinued, subjects will attend a follow-up visit seven (7) days following the last dose&#xD;
      of investigational cream.&#xD;
&#xD;
      Study Duration: This study will last one year from the beginning of subject recruitment to&#xD;
      data analysis.&#xD;
&#xD;
      Participant Duration: Subjects will be enrolled in this study for approximately five (5)&#xD;
      weeks from Screening until the final Study Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hand strength during intervention and at follow-up.</measure>
    <time_frame>Every 2 weeks during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>Grip, appositional, and oppositional pinch strength (kg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with change in The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) during intervention and at follow-up.</measure>
    <time_frame>Every 2 weeks during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>PROMIS-29 will measure health-related quality of life and is a validated, 29 question survey divided into seven sub-domains of function including physical functioning, social function, pain interference, pain intensity, sleep, depression, and anxiety, where a higher score indicates more pain interference.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with change in the PROMIS upper extremity tests during intervention and at follow-up.</measure>
    <time_frame>Every 2 weeks during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>The Patient Reported Outcome Information System (PROMIS) Upper Extremity Computer Adaptive Test (CAT) is a computerized assessment measuring the physical function of the upper extremity. It is scored using a T-score, and the average is 50 for the U.S. population. In a given PROMIS, a T-score above 50 represents more of the measured variable than the average. For this variable, a T-score above 50 indicates greater physical function than the average population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Kapandji score</measure>
    <time_frame>Every 2 weeks during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hand range of motion</measure>
    <time_frame>Every 2 weeks during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>metacarpal phalangeal (MP) and interphalangeal (IP) range of motion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of side effects using novel CBD cream.</measure>
    <time_frame>Daily during intervention and 1 week washout, up to 5 weeks.</time_frame>
    <description>Side effects will be assessed at each encounter clinical evaluation by patient report in a Symptom Diary. All side effects thought to be secondary to CBD will be documented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>CBD</condition>
  <condition>Hand Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Start with CBD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Start with control (Shea butter)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>Topical CBD application for thumb basal joint osteoarthritis.</description>
    <arm_group_label>Start with CBD</arm_group_label>
    <arm_group_label>Start with control (Shea butter)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shea Butter</intervention_name>
    <description>Placebo Shae Butter for comparison</description>
    <arm_group_label>Start with CBD</arm_group_label>
    <arm_group_label>Start with control (Shea butter)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form.&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          3. Male or female, aged 18 years or older.&#xD;
&#xD;
          4. Females of childbearing potential must have a negative urine and blood pregnancy test&#xD;
             at Screening and a negative urine pregnancy test before study drug is administered.&#xD;
             Females must abstain from sex or use a highly effective method of contraception during&#xD;
             the period from Screening to administration of study drug and for 30 days after the&#xD;
             last dose of study medication. Standard acceptable methods include abstinence or the&#xD;
             use of a highly effective method of contraception, including; hormonal contraception,&#xD;
             diaphragm, cervical cap, vaginal sponge, condom with spermicide, vasectomy,&#xD;
             intrauterine device. If females are of non-child bearing potential, they must be&#xD;
             post-menopausal defined as: age &gt; 55 with no menses within the past 12 months, or&#xD;
             history of hysterectomy, or history of bilateral oophorectomy, or bilateral tubal&#xD;
             ligation.&#xD;
&#xD;
          5. Males must consent to use a medically acceptable method of contraception throughout&#xD;
             the entire study period and for 90 days after their last study drug application. They&#xD;
             must agree to not donate sperm for 90 days after their last study drug application.&#xD;
&#xD;
          6. Presence of radiographically confirmed diagnosis of thumb basal joint arthritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Subject does not speak English.&#xD;
&#xD;
          2. Severe cardiac, pulmonary, liver and /or renal disease.&#xD;
&#xD;
          3. Coumadin use at time of screening.&#xD;
&#xD;
          4. History of mental illness.&#xD;
&#xD;
          5. Pregnancy or breast feeding at time of screening.&#xD;
&#xD;
          6. Subjects who are incarcerated.&#xD;
&#xD;
          7. History of drug or substance abuse.&#xD;
&#xD;
          8. Pre-existing CBD or hemp based product usage.&#xD;
&#xD;
          9. Subject has had a corticosteroid injection â‰¤ 3 months prior.&#xD;
&#xD;
         10. Subject has had prior surgery for osteoarthritis treatment.&#xD;
&#xD;
         11. Females who are pregnant, nursing or planning a pregnancy; females of childbearing&#xD;
             potential who are unwilling or unable to use an acceptable method of contraception as&#xD;
             outlined in this protocol from Screening to the first dose of study medication and for&#xD;
             30 days after the last dose of study medication. Standard acceptable methods include&#xD;
             abstinence or the use of a highly effective method of contraception, including;&#xD;
             hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom with&#xD;
             spermicide, vasectomy, intrauterine device.&#xD;
&#xD;
         12. Any skin disease or condition, including eczema, psoriasis, melanoma, acne or contact&#xD;
             dermatitis, scarring, imperfections, lesions, tattoos or discoloration that may affect&#xD;
             treatment application, application site assessments, or affect absorption of the study&#xD;
             drug.&#xD;
&#xD;
         13. Subjects with ALT/AST &gt;3 times the upper limit of normal at screening.&#xD;
&#xD;
         14. Subjects with history of or active depression or suicide ideation based on&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
         15. Subjects taking prescription or non-prescription medication which are substrates of&#xD;
             CYP3A4, CYP2C19, CYP2C8, CYP2C9, CYP2C19, CYP1A2 and CYP2B6 within 14 days of the&#xD;
             study procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Heineman, MD, MPH</last_name>
    <phone>641-990-6515</phone>
    <email>jth4y@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent DeGeorge, MD, PhD</last_name>
      <phone>434-760-3297</phone>
      <email>bd6u@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Timko, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brent DeGeorge, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>John Heineman, MD</investigator_full_name>
    <investigator_title>Plastic Surgery Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

